15 results on '"AMSP"'
Search Results
2. Treatment of depression: Are psychotropic drugs appropriately dosed in women and in the elderly? Dosages of psychotropic drugs by sex and age in routine clinical practice.
- Author
-
Greil, Waldemar, de Bardeci, Mateo, Seifert, Johanna, Bernegger, Xueqiong, Cattapan, Katja, Stassen, Hans, Wagner, Anita L., Sieberer, Marcel, Grohmann, Renate, and Toto, Sermin
- Subjects
- *
OLDER women , *PSYCHIATRIC drugs , *DRUG dosage , *MENTAL depression , *AGE differences - Abstract
Background: Several researchers have shown higher concentration‐dose ratios of psychotropic drugs in women and the elderly. Therefore, lower dosages of psychotropic drugs may be recommended in women and the elderly. This study describes sex‐ and age‐related dosage of psychotropic drugs prescribed to patients with major depressive disorder (MDD) in routine clinical practice. Method: Influence of sex and age on dosages are analysed for the 10 most commonly prescribed drugs in our dataset consisting of 32,082 inpatients with MDD. Data stems from the European drug safety program "Arzneimittelsicherheit in der Psychiatrie". The observed sex and age differences in prescriptions are compared to differences described in literature on age‐ and gender‐related pharmacokinetics. Results: Among patients over 65 years, a statistically significant decrease in dosages with increasing age (between 0.65% and 2.83% for each increasing year of age) was observed, except for zopiclone. However, only slight or no influence of sex‐related adjustment of dosage in prescriptions was found. Conclusion: Age appears to influence adjustment of dosage in most psychotropic drugs, but to a lower extent than data on age‐related pharmacokinetics suggests. Although literature also suggests that lower dosages of psychotropic drugs may be appropriate for females, this study found women are usually prescribed the same dosage as men. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.
- Author
-
Reinhard, Matthias A., Seifert, Johanna, Greiner, Timo, Toto, Sermin, Bleich, Stefan, and Grohmann, Renate
- Subjects
- *
POST-traumatic stress disorder , *DRUG therapy , *DRUG utilization , *PSYCHOTHERAPY , *DIAGNOSIS - Abstract
Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder with limited approved pharmacological treatment options and high symptom burden. Therefore, real-life prescription patterns may differ from guideline recommendations, especially in psychiatric inpatient settings. The European Drug Safety Program in Psychiatry ("Arzneimittelsicherheit in der Psychiatrie", AMSP) collects inpatients' prescription rates cross-sectionally twice a year in German-speaking psychiatric hospitals. For this study, the AMSP database was screened for psychiatric inpatients with a primary diagnosis of PTSD between 2001 and 2017. N = 1,044 patients with a primary diagnosis of PTSD were identified with 89.9% taking psychotropics. The average prescription rate was 2.4 (standard deviation: 1.5) psychotropics per patient with high rates of antidepressant drugs (72.0%), antipsychotics drugs (58.4%) and tranquilizing drugs (29.3%). The presence of psychiatric comorbidities was associated with higher rates of psychotropic drug use. The most often prescribed substances were quetiapine (24.1% of all patients), lorazepam (18.1%) and mirtazapine (15.0%). The use of drugs approved for PTSD was low (sertraline 11.1%; paroxetine 3.7%). Prescription rates of second-generation antipsychotic drugs increased, while the use of tranquilizing drugs declined over the years. High prescription rates and extensive use of sedative medication suggest a symptom-driven prescription (e.g., hyperarousal, insomnia) that can only be explained to a minor extent by existing comorbidities. The observed discrepancy with existing guidelines underlines the need for effective pharmacological and psychological treatment options in psychiatric inpatient settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016.
- Author
-
Schneider, Michael, Pauwels, Philipp, Toto, Sermin, Bleich, Stefan, Grohmann, Renate, Heinze, Martin, and Greiner, Timo
- Subjects
- *
DRUG side effects , *WEIGHT gain , *BODY mass index , *BODY weight , *ANTIDEPRESSANTS - Abstract
Severe weight gain induced by psychotropics is a known problem in psychiatry. Various drugs from different classes may lead to weight gain that may further lead to potentially life-shortening diseases, such as diabetes or cardiovascular disease. A total of 344 cases of severe weight gain (>10% of body weight) have been documented by the drug safety in psychiatry program AMSP between 2001 and 2016. Patients gained 12.7 ± 5.5 kg weight within 12±15 weeks. This equals a Body Mass Index (BMI) gain of 4.4 ± 1.9 kg/m² to a final BMI of 28.8 ± 5.5 kg/m². In addition, 142 retrospective reports documented at admission have been analyzed. Within one year these patients gained 6.4 ± 4.0 kg/m² to a final BMI of 31.9 kg/m². The weight gain was extreme in some cases. For example, 35% of the patients gained more than 20 kg. On average the patients reached overweight or even adiposity. Only 27% of the patients could loose some weight at the end of their stay. This emphasizes the relevance of this long-term problem for the patients' health. Mostly second generation antipsychotics, and therein olanzapine, as well as antidepressants and anticonvulsants have been imputed. Severe weight gain is a slow process and it is rarely documented as adverse drug reaction under real-life conditions compared to the high percentage of patients with weight gain in clinical studies. It might often remain unnoticed due to shorter stationary treatment and changing treatment settings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme.
- Author
-
Mörkl, Sabrina, Seltenreich, Daniel, Letmaier, Martin, Bengesser, Susanne, Wurm, Walter, Grohmann, Renate, Bleich, Stefan, Toto, Sermin, Stübner, Susanne, Butler, Mary I., and Kasper, Siegfried
- Subjects
- *
ANTIDEPRESSANTS , *DRUG utilization , *SEROTONIN uptake inhibitors , *DRUG side effects - Abstract
Objectives: Extrapyramidal symptoms (EPS) are a common adverse effect of antipsychotics. However, there are case reports describing EPS following treatment with antidepressants. It is not fully understood how antidepressants cause EPS, but a serotonergic input to dopaminergic pathways is a probable mechanism of action. Methods: Data from a multicenter drug-surveillance programme (AMSP, 'drug safety in psychiatry') which systemically documents severe drug reactions during psychiatric inpatient admissions, were reviewed to assess for EPS associated with antidepressant treatment. We identified 15 such cases, which were studied to detect similarities and to characterise risk factors. Results: We report on 15 patients with EPS following antidepressant-therapy between 1994 and 2016. EPS frequently occurred with selective serotonin reuptake inhibitor (SSRI) treatment alone (7/15 cases) or concomitant SSRI treatment (6/15 cases). EPS were most frequent with escitalopram-treatment (5 cases). The most common EPS was atypical dyskinesia (6/15 cases) followed by akathisia (4/15 cases). The mean age of onset for EPS was 54.93 years (SD 17.9). EPS occurred at any dosage and equally often in men and women. Conclusions: Our results highlight the possibility of EPS as an important, although uncommon, adverse effect of antidepressants. Clinicians should beware of this adverse effect and monitor early warning signs carefully. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016.
- Author
-
Greiner, Timo, Haack, Beatrice, Toto, Sermin, Bleich, Stefan, Grohmann, Renate, Faltraco, Frank, Heinze, Martin, and Schneider, Michael
- Subjects
- *
ADJUSTMENT disorders , *DRUG therapy , *PSYCHOTHERAPY , *PSYCHIATRIC drugs , *ANTIPSYCHOTIC agents - Abstract
Adjustment disorder is a temporary change in behaviour or emotion as a reaction to a stress factor. Therapy consists of psychotherapy, and pharmacotherapy can be advised. However, data on the real-life pharmacological treatment are sparse. Prescription data for 4.235 psychiatric inpatients diagnosed with adjustment disorder in the time period 2000–2016 were analysed. The data were obtained from the Drug Safety Programme in Psychiatry (AMSP). Data were collected on two reference days per year; prescription patterns and changes over time were analysed. Of all patients, 81.2% received some type of psychotropic drug. Mostly antidepressants (59.8%), antipsychotics (35.5%), and tranquilisers (22.6%) were prescribed. Prescription rates for antidepressants decreased slightly over the years, while rates for antipsychotics increased, especially for atypical antipsychotics. It is important to note that the diagnosis "adjustment disorder" is most likely a working diagnosis that is used for patients in immediate need of psychiatric aid. Overall, pharmacotherapy for inpatients with this diagnosis is mostly symptom-oriented and focuses on depressive moods, agitation and anxiety. Therapy regimes changed over time and show an increased use of atypical antipsychotics with sedative properties. However, for most of the medication, there are neither evidence-based studies nor guidelines, and drugs might be contraindicated in some cases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.
- Author
-
Toto, Sermin, Grohmann, Renate, Bleich, Stefan, Frieling, Helge, Maier, Hannah B, Greil, Waldemar, Cordes, Joachim, Schmidt-Kraepelin, Christian, Kasper, Siegfried, Stübner, Susanne, Degner, Detlef, Druschky, Katrin, Zindler, Tristan, and Neyazi, Alexandra
- Subjects
PSYCHIATRIC drugs ,ARIPIPRAZOLE ,DRUG therapy ,SCHIZOPHRENIA ,AMISULPRIDE ,ANTIPSYCHOTIC agents ,TRANQUILIZING drugs - Abstract
Background Psychotropic drugs are the cornerstone of schizophrenia treatment, often requiring lifelong treatment. Data on pharmacotherapy in inpatient settings are lacking. Methods Prescription data of schizophrenic inpatients within the time period 2000–2015 were obtained from the database of the Drug Safety Program in Psychiatry (AMSP). Data were collected at 2 index dates per year; the prescription patterns and changes over time were analyzed. Results Among 30 908 inpatients (mean age 41.6 years, 57.8% males), the drug classes administered most often were antipsychotics (94.8%), tranquilizers (32%), antidepressants (16.5%), antiparkinsonians (16%), anticonvulsants (14.1%), hypnotics (8.1%), and lithium (2.1%). The use of second-generation antipsychotics significantly increased from 62.8% in 2000 to 88.9% in 2015 (P < .001), whereas the prescription of first-generation antipsychotics decreased from 46.6% in 2000 to 24.7% in 2015 (P < .001). The administration of long-acting injectable antipsychotics decreased from 15.2% in 2000 to 11.7% in 2015 (P = .006). Clopazine was the most often used antipsychotic, having been used for 21.3% of all patients. Polypharmacy rates (≥5 drugs) increased from 19% in 2000 to 26.5% in 2015. Psychiatric polypharmacy (≥3 psychotropic drugs) was present in 44.7% of patients. Conclusions Combinations of antipsychotics and augmentation therapies with other drug classes are frequently prescribed for schizophrenic patients. Though treatment resistance and unsatisfactory functional outcomes reflect clinical necessity, further prospective studies are needed on real-world prescription patterns in schizophrenia to evaluate the efficacy and safety of this common practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries
- Author
-
Johanna Seifert, Stefan Bleich, Sermin Toto, Matthias Reinhard, Renate Grohmann, and Timo Greiner
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Mirtazapine ,Guideline ,Drug Prescriptions ,Stress Disorders, Post-Traumatic ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Germany ,medicine ,Humans ,Pharmacology (medical) ,Medical prescription ,Psychiatry ,Antipsychotic ,Biological Psychiatry ,Psychotropic Drugs ,Original Paper ,Sertraline ,AMSP ,business.industry ,Posttraumatic stress disorder ,PTSD ,General Medicine ,Paroxetine ,Antidepressive Agents ,030227 psychiatry ,Hospitalization ,Psychiatry and Mental health ,Tranquilizing Agents ,Antidepressant ,Quetiapine ,business ,030217 neurology & neurosurgery ,Antipsychotic Agents ,medicine.drug - Abstract
Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder with limited approved pharmacological treatment options and high symptom burden. Therefore, real-life prescription patterns may differ from guideline recommendations, especially in psychiatric inpatient settings. The European Drug Safety Program in Psychiatry (“Arzneimittelsicherheit in der Psychiatrie”, AMSP) collects inpatients’ prescription rates cross-sectionally twice a year in German-speaking psychiatric hospitals. For this study, the AMSP database was screened for psychiatric inpatients with a primary diagnosis of PTSD between 2001 and 2017. N = 1,044 patients with a primary diagnosis of PTSD were identified with 89.9% taking psychotropics. The average prescription rate was 2.4 (standard deviation: 1.5) psychotropics per patient with high rates of antidepressant drugs (72.0%), antipsychotics drugs (58.4%) and tranquilizing drugs (29.3%). The presence of psychiatric comorbidities was associated with higher rates of psychotropic drug use. The most often prescribed substances were quetiapine (24.1% of all patients), lorazepam (18.1%) and mirtazapine (15.0%). The use of drugs approved for PTSD was low (sertraline 11.1%; paroxetine 3.7%). Prescription rates of second-generation antipsychotic drugs increased, while the use of tranquilizing drugs declined over the years. High prescription rates and extensive use of sedative medication suggest a symptom-driven prescription (e.g., hyperarousal, insomnia) that can only be explained to a minor extent by existing comorbidities. The observed discrepancy with existing guidelines underlines the need for effective pharmacological and psychological treatment options in psychiatric inpatient settings.
- Published
- 2020
9. Impact of an Anti-Microbial Stewardship Program on Targeted Antimicrobial Therapy in a Tertiary Care Health Care Institute in Central India
- Author
-
Lily Podder, Mamta Verma, Sagar Khadanga, Shweta Kumar, Gyanendra Singh, Vaibhav Ingle, Tadepalli Karuna, Saurabh Saigal, Abhishek Singhai, Kamini Walia, and Rahul Garg
- Subjects
medicine.medical_specialty ,antimicrobial stewardship program ,Microbiological culture ,medicine.diagnostic_test ,medicine.drug_class ,business.industry ,Antibiotics ,General Engineering ,Prevalence ,Infectious Disease ,Antimicrobial ,targeted therapy ,amsp ,Antibiotic resistance ,Internal medicine ,medicine ,Internal Medicine ,Antimicrobial stewardship ,Blood culture ,Medical prescription ,business ,point prevalence survey (pps) ,bacterial culture rate - Abstract
Introduction Antimicrobial resistance (AMR) has become a global pandemic. In order to identify this menace, World Health Organisation (WHO) has developed the Global Action Plan on AMR (GAP AMR). Antimicrobial stewardship programs (AMSP) have been identified as a decisive tool for combating AMR. One of the most efficient measures of these programs has been the implementation of point prevalence surveys (PPS) of antibiotic usage and subsequent audit feedback. The present study was undertaken to identify the impact of AMSP on curtailing of empirical usage of antibiotics and the augmentation of targeted therapy. Methods It is an observational, cross-sectional study comprising 1396 patients. The microbiology culture details and anti-microbial-sensitivity results were recorded. Antibiotic prescriptions were recorded in each patient during their hospital stay. Result Out of 1396 patients treated over four quarters (Q1-Q4), 711 (50.9%) patients were on antibiotics, and among them, only 415 patients were subjected to any microbiological cultures with an overall bacterial culture rate (BCR) of 58.3%, and 296 patients (41.6%) were treated with antibiotics empirically without sending any samples for bacterial culture. There was a statistically significant rise in BCR from 47.3% in the first quarter to 77.6% in the fourth quarter. Sending specimens for blood culture increased significantly from 29.2% in Q1 to 37.6% in Q4. After receiving culture reports, 72.3% of cases continued with the same antibiotic, the antibiotic was changed in 19.9% of cases, and the antibiotic was stopped in 7.8% of cases. Conclusion There was a strong positive impact of AMSP in curtailment of empirical usage of antibiotics and augmenting targeted therapy as evidenced by the significant rise in BCR over Q1-Q4 PPS as well as a significant rise in ordering for blood culture over the same time period.
- Published
- 2021
10. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
- Author
-
Poppe, Christine, Müller, Sabrina T., Greil, Waldemar, Walder, Alice, Grohmann, Renate, and Stübner, Susanne
- Subjects
- *
OBSESSIVE-compulsive disorder , *MENTAL health services , *COGNITIVE therapy , *MEDICAL practice , *DRUG therapy , *INPATIENT care , *ANTIDEPRESSANTS , *TRANQUILIZING drugs , *ANTIPSYCHOTIC agents , *SEROTONIN uptake inhibitors , *CLOMIPRAMINE , *CROSS-sectional method , *THERAPEUTICS - Abstract
Background: Specific treatment of obsessive compulsive disorder (OCD) is based on cognitive-behavioral therapy, serotonin reuptake inhibitors (SRIs) or their combination. Treatment strategies do not always follow evidence-based guidelines in outpatient settings. Data on pharmacotherapy in inpatient settings are lacking.Methods: Prescription data for inpatients suffering from OCD in the time period 1994-2012 were obtained from the database of the Drug Safety Program in Psychiatry (AMSP). Data were collected on two index dates per year; the prescription patterns and changes over time were analysed.Results: Of 842 patients 89.9% received at least one psychotropic drug and 67.6% a combination of at least two psychotropic drugs. The drug groups prescribed most often were antidepressants (78.0%), antipsychotics (46.7%), and tranquilizers (19.7%). In 58.0% of all cases selective serotonin reuptake inhibitors (SSRIs) were used as antidepressants, followed by tricyclic antidepressants (TCAs, 17.8%), mainly clomipramine (10.9%). Second-generation antipsychotics (SGAs) were administered in 37.8% of all cases, first-generation antipsychotics (FGAs) in 13.7%. While the use over time significantly increased for psychotropic drugs, antidepressants, antipsychotics, tranquilizers, SSRIs and SGAs, it remained stable for FGAs and decreased for TCAs.Limitations: Observational cross-sectional study without follow-up or additional information.Conclusions: In clinical practice, most OCD patients received pharmacological treatment. The high prescription rate of SSRIs and their preference over clomipramine as well as the augmentation of this therapy with SGAs comply with the guidelines. Administration of tranquilizers as well as sedative FGAs and the choice of single SGAs are not in line with expert recommendations. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study.
- Author
-
Kleimann, Alexandra, Schrader, Viktoria, Stübner, Susanne, Greil, Waldemar, Kahl, Kai G., Bleich, Stefan, Grohmann, Renate, Frieling, Helge, and Toto, Sermin
- Subjects
- *
PSYCHOPHARMACOLOGY , *PATIENTS , *DATABASES , *ANTICONVULSANTS , *MUSCLE relaxants , *ANTIDEPRESSANTS , *BENZODIAZEPINES , *VALPROIC acid , *LITHIUM compounds , *TRANQUILIZING drugs , *ANTIPSYCHOTIC agents , *BIPOLAR disorder , *MEDICAL prescriptions , *CROSS-sectional method , *ACUTE diseases , *THERAPEUTICS - Abstract
Background: Several studies have analyzed prescription patterns for bipolar disorder, but few have for acute mania. Treatment strategies in this complex domain change over time and do not always follow evidence-based guidelines.Methods: Prescription data of in-patients suffering from acute mania in the time period from 2005 to 2012 were obtained from the database of the Drug Safety Program in Psychiatry (Institut für Arzneimittelsicherheit in der Psychiatrie; AMSP). Data were collected on two index dates per year. Changes over time were analyzed comparing the time periods 2005/06 and 2011/12.Results: Among 1650 patients (mean ±SD; age: 48.9±14.91 years; 53.1% females) 54.1% received anticonvulsants, 74.5% second-generation antipsychotics (SGAs), 17.8% first-generation antipsychotics (FGAs), 29.1% lithium, 44.1% benzodiazepines and 14.5% antidepressants. Prescription of SGAs increased from 70% to 79% (p=0.005), while prescription of FGAs and anticonvulsants decreased from 19% to 13% (p<0.05) and 59% to 46% (p<0.001), respectively. Only 30% of patients received monotherapy with one mood stabilizer. We observed an impact of gender, age and psychotic symptoms on treatment strategy. 36.8% of the women≤40 years received valproate.Limitations: Follow-up data are missing and no differentiation between acute and maintenance treatments could be made due to the cross-sectional design. Additionally, our findings do not necessarily translate to outpatients or to other countries.Conclusions: Combination therapies represent standard clinical practice. Though many results reflect clinical necessity, the high number of antidepressant prescriptions or valproate use in women of child-bearing age should be judged critically. Further prospective studies should focus on real-world prescription practice in acute mania to evaluate efficacy and safety of common practice. This paper is dedicated to Prof. Dr. Hanns Hippius on the occasion of his 90th birthday. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009
- Author
-
Greil, Waldemar, Häberle, Anne, Haueis, Patrick, Grohmann, Renate, and Russmann, Stefan
- Subjects
- *
MENTAL illness drug therapy , *INPATIENT care , *PEOPLE with bipolar disorder , *SCIENTIFIC observation , *CROSS-sectional method , *PSYCHIATRIC hospitals , *ANTIDEPRESSANTS - Abstract
Abstract: Background: Pharmacological treatment of bipolar depression is a complex and controversial issue, and its real-world practice remains largely unknown. Method: Observational analysis of the pharmacotherapy of 2231 psychiatric inpatients with a current episode of bipolar depression. The study was based on cross-sectional prescription data from European psychiatric hospitals that had been repeatedly collected between 1994 and 2009 through the collaborative Drug Safety in Psychiatry (AMSP) program. Results: Overall 81.3% of patients received antidepressants (AD) (7.8% monotherapy), 57.9% antipsychotics (AP), 50.1% anticonvulsants (AC), 47.5% tranquilizers, and 34.6% lithium (Li). Use over time was stable for AD, decreased for Li, and increased for AC, AP and tranquilizers. Pronounced increases were specifically observed for quetiapine, lamotrigine and valproate. Use of tricyclic AD decreased but its prevalence was still 11.8% in 2009. Venlafaxine was used by 19.5% in 2009. We also observed an increase of polypharmacy combining AD, AP, AC and Li. From 2006 to 2009 37.0% received concomitant treatment with three, and 6.4% even with all four of those drug classes. Limitations: Observational cross-sectional study without follow-up or additional clinical information. Conclusions: Monotherapy with antidepressants and any use of tricyclic AD and venlafaxine still has a considerable prevalence in bipolar depression, but this is controversial due to the reported risk of treatment emergent affective switches. Triple and quadruple therapy is not evidence-based but increasingly used in clinical practice. This may reflect an attempt to overcome treatment failure, and further studies should evaluate efficacy and safety of this common practice. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
13. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.
- Author
-
Haeberle, Anne, Greil, Waldemar, Russmann, Stefan, and Grohmann, Renate
- Subjects
- *
MENTAL depression , *ANTIDEPRESSANTS , *ANTICONVULSANTS , *VALPROIC acid , *LAMOTRIGINE - Abstract
Background: For the pharmacological treatment of bipolar depression several guidelines exist. It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used. Methods: The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression (n = 2246; time period 1994-2009) from hospitals participating in the drug surveillance program AMSP. For the drug use in 2010, 221 cases were analysed additionally. Results: From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74% received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When given in combination, lithium is the most often prescribed substance for bipolar depression (33%), followed by valproic acid (23%), mirtazapine and venlafaxine (16% each), quetiapine (15%), lamotrigine (14%) and olanzapine (13%). Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI), but also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and combined) was the most frequently prescribed drug (39%); aripiprazole was administered in 10%. Conclusion: Combinations of antidepressants (SSRI, mirtazapine, venlafaxine) with mood stabilizers (lithium, valproic acid, lamotrigine) and / or atypical antipsychotics (quetiapine, olanzapine) are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. UnerwünschteWirkungen unter Therapie mit Psychopharmaka im Alter -- Spezielle Risiken, Schutzmechanismen, Prognosen.
- Author
-
Walder, A. and Greil, W.
- Subjects
- *
DRUG side effects , *PSYCHIATRIC drugs , *DISEASE prevalence , *DISEASES , *POLYPHARMACY , *PSYCHIATRY , *QUALITY of life , *PROGNOSIS - Abstract
Due to their multimorbidity elderly patients take multiple medications, which increase the risks of adverse side effects. In this patient group,main aim of treatment is to achieve an optimal quality of live. Unwanted effects of drugs and of drug combinations (polypharmacy) have carefully to be checked. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Impact of an Anti-Microbial Stewardship Program on Targeted Antimicrobial Therapy in a Tertiary Care Health Care Institute in Central India.
- Author
-
Garg R, Singh G, Kumar S, Verma M, Podder L, Ingle V, Singhai A, Karuna T, Saigal S, Walia K, and Khadanga S
- Abstract
Introduction Antimicrobial resistance (AMR) has become a global pandemic. In order to identify this menace, World Health Organisation (WHO) has developed the Global Action Plan on AMR (GAP AMR). Antimicrobial stewardship programs (AMSP) have been identified as a decisive tool for combating AMR. One of the most efficient measures of these programs has been the implementation of point prevalence surveys (PPS) of antibiotic usage and subsequent audit feedback. The present study was undertaken to identify the impact of AMSP on curtailing of empirical usage of antibiotics and the augmentation of targeted therapy. Methods It is an observational, cross-sectional study comprising 1396 patients. The microbiology culture details and anti-microbial-sensitivity results were recorded. Antibiotic prescriptions were recorded in each patient during their hospital stay. Result Out of 1396 patients treated over four quarters (Q1-Q4), 711 (50.9%) patients were on antibiotics, and among them, only 415 patients were subjected to any microbiological cultures with an overall bacterial culture rate (BCR) of 58.3%, and 296 patients (41.6%) were treated with antibiotics empirically without sending any samples for bacterial culture. There was a statistically significant rise in BCR from 47.3% in the first quarter to 77.6% in the fourth quarter. Sending specimens for blood culture increased significantly from 29.2% in Q1 to 37.6% in Q4. After receiving culture reports, 72.3% of cases continued with the same antibiotic, the antibiotic was changed in 19.9% of cases, and the antibiotic was stopped in 7.8% of cases. Conclusion There was a strong positive impact of AMSP in curtailment of empirical usage of antibiotics and augmenting targeted therapy as evidenced by the significant rise in BCR over Q1-Q4 PPS as well as a significant rise in ordering for blood culture over the same time period., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2021, Garg et al.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.